Lifestyle

Curocell Inc.’s “Limcato” to Be Covered by National Health Insurance Starting in December… Price Per Dose: 280 Million Won

KIM JI-WAN
2026-11-20 17:18:01
[Edaily Reporter KIM JI-WAN ] “Limcato,” developed by Curocell Inc. and Korea’s first domestically produced chimeric antigen receptor T-cell (CAR-T) therapy, is set to be covered by the National Health Insurance. This is expected to significantly reduce the financial burden on patients with relapsed or refractory large B-cell lymphoma, for whom treatment has been difficult to access due to high costs.



Curocell Inc.(372320)Curocell announced on the 20th that it has completed price negotiations with the National Health Insurance Service (NHIS) for its CAR-T therapy “Limcato” (generic name: anvalcapten-autolysate) and that the matter has been submitted to the Ministry of Health and Welfare’s Health Insurance Policy Deliberation Committee.

The maximum insurance-covered price per dose of Limkato has been set at 280,016,050 won. The company expects health insurance coverage to take effect on December 1, following deliberation by the Committee and the relevant notification procedures.

Limkato is a personalized cell therapy in which T cells collected from a patient are genetically engineered to attack cancer cells and then reinfused into the patient. While a single dose is expected to provide long-term therapeutic effects, the cost—running into the hundreds of millions of won—has historically limited patients’ access to treatment.

On April 29, Rimkato received formal marketing authorization from the Ministry of Food and Drug Safety, becoming the 42nd domestically developed new drug. Subsequently, it passed the National Health Insurance Service’s deliberation on reimbursement criteria in July and received conditional approval for reimbursement from the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee in September.

Clinical results have also been confirmed. In Phase 2 clinical trials, Limcato recorded an objective response rate (ORR) of 75.3% and a complete remission (CR) rate of 67.1%. These figures represent the percentage of treated patients whose tumor size decreased or who reached a state where no cancer was detectable.

Curocell Inc. is preparing for supply and administration in collaboration with major medical institutions, including tertiary general hospitals, in time for the start of coverage. The company plans to manage the entire process—from cell collection from patients through manufacturing, hospital transport, and administration—to minimize treatment delays.

Kim Geon-soo, CEO of Curocell Inc., stated, “With Limkato, Korea’s first domestically developed CAR-T therapy, now covered by national health insurance, we can provide tangible treatment opportunities to patients who previously hesitated to seek treatment due to cost concerns.” He added, “In preparation for coverage taking effect on December 1, we will work closely with medical institutions to ensure our supply system operates smoothly, enabling patients in need to receive treatment quickly and reliably.”

Meanwhile, Curocell Inc. is also pursuing follow-up clinical trials to expand Limcato’s treatment indications. Last month, the company applied for approval to amend its Phase 3 clinical trial protocol to expand the indication to second-line treatment, and aims to begin the trial in the first half of next year.

Economy

Corporation

IT·Science

Economy

High Interest Rates and Deteriorating Creditworthiness: A ‘Double Whammy’… Warning Signs as 23 Companies Face Rating Downgrades

As the prolonged period of high interest rates increases the refinancing burden on companies, warning signs of credit rating downgrades have emerged, particularly in sectors experiencing sluggish busi…
2026-11-20 16:10:05

Corporation

Curocell Inc.’s “Limcato” to Be Covered by National Health Insurance Starting in December… Price Per Dose: 280 Million Won

“Limcato,” developed by Curocell Inc. and Korea’s first domestically produced chimeric antigen receptor T-cell (CAR-T) therapy, is set to be covered by the National Health Insurance. This is expected …
2026-11-20 17:18:01

IT·Science

CJ ENM CO., Ltd. Files for Preliminary Injunction to Halt LG HelloVision Channel Broadcasts… “We Will Protect Viewers’ Right to Choose”

CJ ENM CO., Ltd.(035760)has filed a petition for a preliminary injunction with the court, asking it to prevent LG HelloVision(037560)from suspending broadcasts on its four channels. CJ ENM CO., Ltd…
2026-11-20 17:17:14